REDWOOD CITY, Calif.--(BUSINESS WIRE)--Proteus Digital Health™ announced today that Uneek Mehra has joined the company as Chief Financial Officer. Mr. Mehra has more than twenty years of global finance experience and was previously a senior leader in finance at Novartis, one of the world’s largest global pharmaceutical companies. He has managed substantial P&Ls and through his experience is well-positioned to help Proteus realize its capital markets ambitions.
“R&D productivity in pharma - the key to industry viability - has been halving every 7 years for 5 decades. Joining Proteus on the cusp of defining a new therapeutic category that integrates silicon and software into the pharmaceutical industry’s products and innovation tool kit is a tremendous opportunity to reverse that trend. I am delighted to join the company as Chief Financial Officer,” said Uneek Mehra. “Now is the perfect time for Proteus to accelerate its leadership position in the development and commercialization of Digital Medicines.”
As Chief Financial Officer Mr. Mehra will lead the Finance, IT, People and Facilities teams. He will be a key driver of growth as Proteus expands its commercial footprint in the US and Asia, both directly and through partnerships with pharmaceutical companies.
Mr. Mehra has deep experience across pharmaceuticals, technology and financial services, through senior roles at Novartis, IBM and Citibank. At Novartis, he had responsibilities in Corporate Finance, Commercial Finance, Corporate Business Development and Treasury across the US, Switzerland and China. His pharmaceutical business exposure includes Primary Care, Specialty Care and Oncology. These businesses included products across the entire industry lifecycle from early research to established medicines.
Proteus Co-Founder and Chief Executive Officer Andrew Thompson said, “Uneek Mehra brings extensive industry acumen to Proteus. For more than a decade he has observed that solving the problem of patient adherence to medication, and enabling doctors to more effectively prescribe the right drug to the right patient at the right time, is a market opportunity worth billions.”
About Proteus Digital Health™
Proteus Digital Health is commercializing a new category of therapy: Digital Medicines. These offerings include widely used drugs, formulated so they communicate when they have been swallowed; a wearable patch that detects medicines and captures physiologic response; mobile applications to support patient self-care and physician decision-making; and data analytics to serve the needs of health system managers. Digital Medicines are in commercial use in the United States. Data from both randomized clinical trials and real-world use demonstrate that patients have significantly improved outcomes using Digital Medicines (for example control of blood pressure) and that these outcomes can be sustained.
Proteus Digital Health is privately held by investors that include Carlyle, Essex Woodlands, Kaiser Permanente®, Medtronic®, Novartis®, Otsuka®, Oracle®, and ON Semiconductor®. Further information is available at: www.proteus.com. Connect with us on Twitter @ProteusDH.
